Diosgenin exhibits tumor suppressive function via down-regulation of EZH2 in pancreatic cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Natural Products Research

Background:

• Pancreatic cancer (PC) is a highly lethal malignancy with limited treatment options.
• Enhancer of zeste homolog 2 (EZH2) is an oncogenic protein overexpressed in various cancers, including PC.
• The precise mechanisms underlying PC and potential natural product interventions require further investigation.

Purpose of the Study:

• To investigate the anti-cancer effects of diosgenin in pancreatic cancer cells.
• To elucidate the molecular mechanisms of diosgenin's action, focusing on EZH2 signaling.
• To evaluate diosgenin as a potential therapeutic agent for pancreatic cancer.

Main Methods:

• Treatment of pancreatic cancer cell lines (Patu8988, Panc-1) with varying doses and durations of diosgenin.
• Assessment of cell proliferation, apoptosis, cell cycle progression (G2/M phase), migration, and invasion.
• Analysis of protein expression levels, including EZH2, Vimentin, and PTEN.

Main Results:

• Diosgenin significantly inhibited pancreatic cancer cell proliferation in a dose- and time-dependent manner.
• Diosgenin induced apoptotic cell death and G2/M phase arrest in PC cells.
• Diosgenin reduced cell migration and invasion, decreased EZH2 and Vimentin expression, and increased PTEN expression.

Conclusions:

• Diosgenin exhibits potent anti-cancer properties against pancreatic cancer cells.
• The anti-tumor effects of diosgenin are mediated through the inhibition of EZH2 signaling.
• Diosgenin represents a promising therapeutic candidate for pancreatic cancer treatment by targeting EZH2.